Cargando…
Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment
BACKGROUND: Despite the worldwide campaigns of COVID-19 vaccinations, the pandemic is still a major medical and social problem. The Ortho VITROS SARS-CoV-2 spike-specific quantitative IgG (VITROS S-IgG) assay has been developed to assess neutralizing antibody (NT antibody) against SARS-CoV-2 spike (...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873150/ https://www.ncbi.nlm.nih.gov/pubmed/36693058 http://dx.doi.org/10.1371/journal.pone.0279779 |
_version_ | 1784877539885318144 |
---|---|
author | Takahashi, Maika Saito, Kaori Ai, Tomohiko Nojiri, Shuko Khasawneh, Abdullah Paran, Faith Jessica Horiuchi, Yuki Takei, Satomi Yamamoto, Takamasa Wakita, Mitsuru Hiki, Makoto Miida, Takashi Naito, Toshio Takahashi, Kazuhisa Tabe, Yoko |
author_facet | Takahashi, Maika Saito, Kaori Ai, Tomohiko Nojiri, Shuko Khasawneh, Abdullah Paran, Faith Jessica Horiuchi, Yuki Takei, Satomi Yamamoto, Takamasa Wakita, Mitsuru Hiki, Makoto Miida, Takashi Naito, Toshio Takahashi, Kazuhisa Tabe, Yoko |
author_sort | Takahashi, Maika |
collection | PubMed |
description | BACKGROUND: Despite the worldwide campaigns of COVID-19 vaccinations, the pandemic is still a major medical and social problem. The Ortho VITROS SARS-CoV-2 spike-specific quantitative IgG (VITROS S-IgG) assay has been developed to assess neutralizing antibody (NT antibody) against SARS-CoV-2 spike (S) antibodies. However, it has not been evaluated in Japan, where the total cases and death toll are lower than the rest of the world. METHODS: The clinical performance of VITROS S-IgG was evaluated by comparing with the NT antibody levels measured by the surrogate virus neutralizing antibody test (sVNT). A total of 332 serum samples from 188 individuals were used. Of these, 219 samples were from 75 COVID-19 patients: 96 samples from 20 severe/critical cases (Group S), and 123 samples from 55 mild/moderate cases (Group M). The remaining 113 samples were from 113 healthcare workers who had received 2 doses of the BNT162b2 vaccine. RESULTS: VITROS S-IgG showed good correlation with the cPass sVNT assay (Spearman rho = 0.91). Both VITROS S-IgG and cPass sVNT showed significantly higher plateau levels of antibodies in Group S compared to Group M. Regarding the humoral immune responses after BNT162b2 vaccination, individuals who were negative for SARS-CoV-2 nucleocapsid (N)-specific antibodies had statistically lower titers of both S-IgG and sVNT compared to individuals with a history of COVID-19 and individuals who were positive for N-specific antibodies without history of COVID-19. In individuals who were positive for N-specific antibodies, S-IgG and sVNT titers were similar to individuals with a history of COVID-19. CONCLUSIONS: Although the automated quantitative immunoassay VITROS S-IgG showed a reasonable correlation with sVNT antibodies, there is some discrepancy between Vitros S-IgG and cPass sVNT in milder cases. Thus, VITROS S-IgG can be a useful diagnostic tool in assessing the immune responses to vaccination and herd immunity. However, careful analysis is necessary to interpret the results. |
format | Online Article Text |
id | pubmed-9873150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-98731502023-01-25 Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment Takahashi, Maika Saito, Kaori Ai, Tomohiko Nojiri, Shuko Khasawneh, Abdullah Paran, Faith Jessica Horiuchi, Yuki Takei, Satomi Yamamoto, Takamasa Wakita, Mitsuru Hiki, Makoto Miida, Takashi Naito, Toshio Takahashi, Kazuhisa Tabe, Yoko PLoS One Research Article BACKGROUND: Despite the worldwide campaigns of COVID-19 vaccinations, the pandemic is still a major medical and social problem. The Ortho VITROS SARS-CoV-2 spike-specific quantitative IgG (VITROS S-IgG) assay has been developed to assess neutralizing antibody (NT antibody) against SARS-CoV-2 spike (S) antibodies. However, it has not been evaluated in Japan, where the total cases and death toll are lower than the rest of the world. METHODS: The clinical performance of VITROS S-IgG was evaluated by comparing with the NT antibody levels measured by the surrogate virus neutralizing antibody test (sVNT). A total of 332 serum samples from 188 individuals were used. Of these, 219 samples were from 75 COVID-19 patients: 96 samples from 20 severe/critical cases (Group S), and 123 samples from 55 mild/moderate cases (Group M). The remaining 113 samples were from 113 healthcare workers who had received 2 doses of the BNT162b2 vaccine. RESULTS: VITROS S-IgG showed good correlation with the cPass sVNT assay (Spearman rho = 0.91). Both VITROS S-IgG and cPass sVNT showed significantly higher plateau levels of antibodies in Group S compared to Group M. Regarding the humoral immune responses after BNT162b2 vaccination, individuals who were negative for SARS-CoV-2 nucleocapsid (N)-specific antibodies had statistically lower titers of both S-IgG and sVNT compared to individuals with a history of COVID-19 and individuals who were positive for N-specific antibodies without history of COVID-19. In individuals who were positive for N-specific antibodies, S-IgG and sVNT titers were similar to individuals with a history of COVID-19. CONCLUSIONS: Although the automated quantitative immunoassay VITROS S-IgG showed a reasonable correlation with sVNT antibodies, there is some discrepancy between Vitros S-IgG and cPass sVNT in milder cases. Thus, VITROS S-IgG can be a useful diagnostic tool in assessing the immune responses to vaccination and herd immunity. However, careful analysis is necessary to interpret the results. Public Library of Science 2023-01-24 /pmc/articles/PMC9873150/ /pubmed/36693058 http://dx.doi.org/10.1371/journal.pone.0279779 Text en © 2023 Takahashi et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Takahashi, Maika Saito, Kaori Ai, Tomohiko Nojiri, Shuko Khasawneh, Abdullah Paran, Faith Jessica Horiuchi, Yuki Takei, Satomi Yamamoto, Takamasa Wakita, Mitsuru Hiki, Makoto Miida, Takashi Naito, Toshio Takahashi, Kazuhisa Tabe, Yoko Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment |
title | Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment |
title_full | Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment |
title_fullStr | Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment |
title_full_unstemmed | Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment |
title_short | Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment |
title_sort | performance evaluation of the ortho vitros sars-cov-2 spike-specific quantitative igg test by comparison with the surrogate virus neutralizing antibody test and clinical assessment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873150/ https://www.ncbi.nlm.nih.gov/pubmed/36693058 http://dx.doi.org/10.1371/journal.pone.0279779 |
work_keys_str_mv | AT takahashimaika performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT saitokaori performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT aitomohiko performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT nojirishuko performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT khasawnehabdullah performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT paranfaithjessica performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT horiuchiyuki performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT takeisatomi performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT yamamototakamasa performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT wakitamitsuru performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT hikimakoto performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT miidatakashi performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT naitotoshio performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT takahashikazuhisa performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment AT tabeyoko performanceevaluationoftheorthovitrossarscov2spikespecificquantitativeiggtestbycomparisonwiththesurrogatevirusneutralizingantibodytestandclinicalassessment |